ID29013A - Ligan-ligan reseptor novel thiroid dan metode ii - Google Patents
Ligan-ligan reseptor novel thiroid dan metode iiInfo
- Publication number
- ID29013A ID29013A IDW00200101489A ID20011489A ID29013A ID 29013 A ID29013 A ID 29013A ID W00200101489 A IDW00200101489 A ID W00200101489A ID 20011489 A ID20011489 A ID 20011489A ID 29013 A ID29013 A ID 29013A
- Authority
- ID
- Indonesia
- Prior art keywords
- ligan
- thiroid
- receptor
- novel
- receptor novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9828442.5A GB9828442D0 (en) | 1998-12-24 | 1998-12-24 | Novel thyroid receptor ligands and method II |
Publications (1)
Publication Number | Publication Date |
---|---|
ID29013A true ID29013A (id) | 2001-07-26 |
Family
ID=10844889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IDW00200101489A ID29013A (id) | 1998-12-24 | 1999-12-23 | Ligan-ligan reseptor novel thiroid dan metode ii |
Country Status (19)
Country | Link |
---|---|
US (2) | US6989402B1 (hu) |
EP (1) | EP1144370A2 (hu) |
JP (1) | JP4405088B2 (hu) |
KR (1) | KR20010108032A (hu) |
CN (1) | CN1186332C (hu) |
AU (1) | AU758202B2 (hu) |
BR (1) | BR9916851A (hu) |
CA (1) | CA2356319A1 (hu) |
CZ (1) | CZ20012204A3 (hu) |
GB (1) | GB9828442D0 (hu) |
HU (1) | HUP0104666A3 (hu) |
ID (1) | ID29013A (hu) |
IL (1) | IL143799A0 (hu) |
NO (1) | NO20012931L (hu) |
NZ (1) | NZ512422A (hu) |
RU (1) | RU2001120701A (hu) |
TR (1) | TR200101834T2 (hu) |
WO (1) | WO2000039077A2 (hu) |
ZA (1) | ZA200104932B (hu) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1127882A1 (en) | 2000-01-25 | 2001-08-29 | Pfizer Products Inc. | Tetrazole compounds as thyroid receptor ligands |
US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
FI107018B (fi) * | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatologinen käyttö ja valmiste |
US6395784B1 (en) * | 2000-06-07 | 2002-05-28 | Bristol-Myers Squibb Company | Benzamide ligands for the thyroid receptor |
DE10038007A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Neue Amino-und Amido-Diphenylether für Arzneimittel |
US7163918B2 (en) * | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
GB0029100D0 (en) * | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
EP1347959A1 (de) * | 2000-12-27 | 2003-10-01 | Bayer Aktiengesellschaft | Indol-derivate |
US7504435B2 (en) | 2001-01-31 | 2009-03-17 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for stimulating weight loss and/or for lowering triglycerides in patients |
KR20030072396A (ko) * | 2001-02-08 | 2003-09-13 | 카로 바이오 아베 | 갑상선 수용체 리간드 |
US6777442B2 (en) | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
DE10122443A1 (de) * | 2001-05-09 | 2002-11-14 | Bayer Ag | Amido-Diphenyl-Derivate |
WO2003018515A2 (en) * | 2001-08-24 | 2003-03-06 | Karo Bio Ab | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
GB0120691D0 (en) * | 2001-08-24 | 2001-10-17 | Karobio Ab | Novel Compounds |
ATE313325T1 (de) | 2001-09-26 | 2006-01-15 | Pfizer Prod Inc | Indolcaroboxylsäure als thyroidrezeptor-liganden |
WO2003064369A1 (fr) * | 2002-01-30 | 2003-08-07 | Kissei Pharmaceutical Co., Ltd. | Nouveau ligand de recepteur de l'hormone thyroidienne, preparations medicinales le contenant et leur utilisation |
GB0208384D0 (en) * | 2002-04-11 | 2002-05-22 | Karobio Ab | Novel compounds |
GB0215978D0 (en) * | 2002-07-10 | 2002-08-21 | Karobio Ab | Novel compounds |
KR101025633B1 (ko) * | 2002-09-19 | 2011-03-30 | 일라이 릴리 앤드 캄파니 | 오피오이드 수용체 안타고니스트로서의 디아릴 에테르 |
EP1477475A1 (en) * | 2003-05-16 | 2004-11-17 | Procorde GmbH | Compounds for use as a medicine increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
ITRM20030363A1 (it) * | 2003-07-24 | 2005-01-25 | Fernando Goglia | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. |
PL1689757T3 (pl) * | 2003-11-12 | 2015-05-29 | Sino Med Int Alliance Inc | Heterocykliczne związki kwasu boronowego |
US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) * | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
AU2006249350B2 (en) | 2003-11-19 | 2012-02-16 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
US7504413B2 (en) | 2004-05-06 | 2009-03-17 | Cytokinetics, Inc. | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases |
US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
US7795448B2 (en) | 2004-05-06 | 2010-09-14 | Cytokinetics, Incorporated | Imidazoyl-benzamide anti-cancer agents |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
US7317024B2 (en) | 2005-01-13 | 2008-01-08 | Bristol-Myers Squibb Co. | Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7629342B2 (en) | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
US7317012B2 (en) | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7572808B2 (en) | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
WO2007010885A1 (ja) * | 2005-07-19 | 2007-01-25 | Daiichi Sankyo Company, Limited | 置換プロパンアミド誘導体及びそれを含む医薬組成物 |
RU2008108984A (ru) * | 2005-08-10 | 2009-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Терапевтический агент от диабета |
US7795436B2 (en) | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
AR056155A1 (es) | 2005-10-26 | 2007-09-19 | Bristol Myers Squibb Co | Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica |
WO2007053819A2 (en) | 2005-10-31 | 2007-05-10 | Bristol-Myers Squibb Company | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods |
TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
DK2010493T3 (en) * | 2006-04-12 | 2016-05-02 | Merck Sharp & Dohme | PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS |
WO2007120083A1 (en) * | 2006-04-13 | 2007-10-25 | Astrazeneca Ab | The use of carboxamide derivatives in the manufacture of a medicament for the treatment of inflammatory, allergic and dermatological conditions |
WO2007132475A1 (en) * | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7968577B2 (en) | 2006-11-01 | 2011-06-28 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
US8198311B2 (en) | 2006-11-01 | 2012-06-12 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
JP5362585B2 (ja) * | 2007-01-31 | 2013-12-11 | チバ ホールディング インコーポレーテッド | カチオン性染料 |
WO2008106213A1 (en) | 2007-02-27 | 2008-09-04 | Titan Pharmaceuticals, Inc. | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. |
AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
EP2142551B1 (en) | 2007-04-17 | 2015-10-14 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
JP2010534722A (ja) | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
CN101801954B (zh) * | 2007-09-20 | 2013-10-09 | Irm责任有限公司 | 作为gpr119活性调节剂的化合物和组合物 |
KR20100072266A (ko) * | 2007-10-24 | 2010-06-30 | 머크 샤프 앤드 돔 코포레이션 | 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제 |
JP2011503081A (ja) | 2007-11-01 | 2011-01-27 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、AP−1および/またはNF−κB活性の調節剤として有用な非ステロイド性化合物、並びにその使用 |
GB0725214D0 (en) * | 2007-12-24 | 2008-02-06 | Karobio Ab | Pharmaceutical compounds |
PE20091928A1 (es) | 2008-05-29 | 2009-12-31 | Bristol Myers Squibb Co | Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos |
WO2010049946A2 (en) * | 2008-10-27 | 2010-05-06 | Cadila Healthcare Limited | Thyroid receptor ligands |
WO2010058730A1 (ja) | 2008-11-19 | 2010-05-27 | ポーラ化成工業株式会社 | シワ改善剤 |
WO2010086878A2 (en) | 2009-01-09 | 2010-08-05 | Cadila Healthcare Limited | Thyroid receptor modulators |
EP2411005A1 (en) | 2009-03-27 | 2012-02-01 | Bristol-Myers Squibb Company | Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors |
KR101396606B1 (ko) | 2009-04-20 | 2014-05-16 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 갑상선 호르몬 β 수용체 작동약 |
MX2012005425A (es) | 2009-11-13 | 2012-06-14 | Astrazeneca Uk Ltd | Formulaciones de metformina de masa reducida. |
US8871264B2 (en) | 2009-11-13 | 2014-10-28 | Astrazeneca Ab | Immediate release tablet formulations |
PL2498758T3 (pl) | 2009-11-13 | 2019-02-28 | Astrazeneca Ab | Formulacje tabletek dwuwarstwowych |
WO2011103126A1 (en) * | 2010-02-17 | 2011-08-25 | Ampla Pharmaceuticals Inc. | Treatment of metabolic syndrome with piperidine amides |
EP2558461B1 (en) | 2010-04-14 | 2015-12-02 | Bristol-Myers Squibb Company | Novel glucokinase activators and methods of using same |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
JP5830534B2 (ja) | 2010-07-09 | 2015-12-09 | ファイザー・リミテッドPfizer Limited | 化合物 |
ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
EP2593432B1 (en) | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
CA2800971A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
WO2012007877A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
CN104024251B (zh) | 2011-10-31 | 2017-08-11 | 克赛农制药股份有限公司 | 苯磺酰胺化合物及其作为治疗剂的用途 |
US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
CA2857603C (en) | 2011-12-15 | 2016-08-02 | Pfizer Limited | Sulfonamide derivatives |
CA2860553C (en) * | 2012-01-04 | 2016-08-23 | Pfizer Limited | N-aminosulfonyl benzamides |
TW201400446A (zh) | 2012-05-22 | 2014-01-01 | Genentech Inc | N-取代之苯甲醯胺及其使用方法 |
CN102718718B (zh) * | 2012-05-31 | 2014-09-24 | 绍兴文理学院 | 一种3,5-二溴-4-(5-苯并咪唑氧基)苯乙酸的制备方法 |
KR101663436B1 (ko) * | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
WO2014039411A1 (en) | 2012-09-05 | 2014-03-13 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists |
EP2892897A1 (en) | 2012-09-05 | 2015-07-15 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
BR112015022488A2 (pt) | 2013-03-14 | 2017-07-18 | Genentech Inc | triazolopiridinas substituídas e métodos de uso das mesmas |
BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
WO2015027021A1 (en) | 2013-08-22 | 2015-02-26 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
CR20160296A (es) | 2013-11-27 | 2016-09-20 | Genentech Inc | Benzamidas sustituidas y métodos para usarlas |
CN103709094B (zh) * | 2014-01-07 | 2016-04-06 | 厦门大学 | 4-苯氧基苯甲酰胺类化合物及其制备方法和应用 |
WO2016007534A1 (en) | 2014-07-07 | 2016-01-14 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
EP3297989A1 (en) | 2015-05-22 | 2018-03-28 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
RU2018115718A (ru) | 2015-09-28 | 2019-10-28 | Дженентек, Инк. | Терапевтические соединения и способы их применения |
CN108495851A (zh) | 2015-11-25 | 2018-09-04 | 基因泰克公司 | 取代的苯甲酰胺及其使用方法 |
WO2017172802A1 (en) | 2016-03-30 | 2017-10-05 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
WO2017184604A1 (en) * | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
KR102537274B1 (ko) * | 2016-08-12 | 2023-05-25 | 오레곤 헬스 앤드 사이언스 유니버시티 | 아마이드 화합물, 이의 약학 조성물 및 이들을 이용하는 방법 |
AU2017347549A1 (en) | 2016-10-17 | 2019-05-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CN110198719A (zh) | 2016-11-21 | 2019-09-03 | 维京治疗公司 | 治疗糖原贮积病的方法 |
CN106588690B (zh) * | 2016-12-19 | 2019-06-04 | 广西中医药大学 | 毛鸡骨草甲素Abrusamide的制备方法 |
JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック, インコーポレイテッド | ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体 |
BR112019025659A2 (pt) | 2017-06-05 | 2020-08-25 | Viking Therapeutics, Inc. | composições para o tratamento de fibrose |
US20210154370A1 (en) | 2017-09-14 | 2021-05-27 | Riken | Method for producing retinal tissues |
CN111417622A (zh) * | 2017-10-17 | 2020-07-14 | 诺华炎症研究公司 | 用于治疗与nlrp活性相关的病症的磺胺类及其组合物 |
CN111518770B (zh) | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
WO2019165290A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Pyridine-sulfonamide compounds and their use against pain and related conditions |
KR20200138283A (ko) | 2018-03-22 | 2020-12-09 | 바이킹 테라퓨틱스 인코포레이티드 | 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법 |
EP3774801A1 (en) | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
AU2019304032B2 (en) | 2018-07-19 | 2021-12-09 | Astrazeneca Ab | Methods of treating HFpEF employing dapagliflozin and compositions comprising the same |
CA3122996A1 (en) | 2018-12-12 | 2020-06-18 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
EP3931180A1 (en) | 2019-03-01 | 2022-01-05 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
JPWO2020184720A1 (hu) | 2019-03-13 | 2020-09-17 | ||
WO2021026179A1 (en) * | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
JPWO2022054924A1 (hu) | 2020-09-11 | 2022-03-17 | ||
JPWO2022054925A1 (hu) | 2020-09-11 | 2022-03-17 | ||
CN118302517A (zh) | 2021-11-19 | 2024-07-05 | 国立研究开发法人理化学研究所 | 片状视网膜组织的制造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3231541A1 (de) * | 1982-08-25 | 1984-03-01 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin | Arzneimittel, enthaltend 3,3',5-trijodthyronamin und verfahren zu seiner herstellung |
US4741897A (en) * | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
DK0580550T3 (da) * | 1992-07-21 | 1998-02-02 | Ciba Geigy Ag | Oxamidsyrederivater som hypercholesterolæmiske midler |
WO1996040048A2 (en) | 1995-06-07 | 1996-12-19 | Karo Bio Ab | Novel uses for thyroid hormones or thyroid hormone-like compounds |
US6335459B1 (en) | 1998-12-23 | 2002-01-01 | Syntex (U.S.A.) Llc | Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators |
US6395784B1 (en) * | 2000-06-07 | 2002-05-28 | Bristol-Myers Squibb Company | Benzamide ligands for the thyroid receptor |
-
1998
- 1998-12-24 GB GBGB9828442.5A patent/GB9828442D0/en not_active Ceased
-
1999
- 1999-12-23 AU AU18855/00A patent/AU758202B2/en not_active Ceased
- 1999-12-23 TR TR2001/01834T patent/TR200101834T2/xx unknown
- 1999-12-23 NZ NZ512422A patent/NZ512422A/xx unknown
- 1999-12-23 BR BR9916851-0A patent/BR9916851A/pt not_active IP Right Cessation
- 1999-12-23 EP EP99962486A patent/EP1144370A2/en not_active Withdrawn
- 1999-12-23 CA CA002356319A patent/CA2356319A1/en not_active Abandoned
- 1999-12-23 HU HU0104666A patent/HUP0104666A3/hu unknown
- 1999-12-23 WO PCT/IB1999/002084 patent/WO2000039077A2/en not_active Application Discontinuation
- 1999-12-23 CZ CZ20012204A patent/CZ20012204A3/cs unknown
- 1999-12-23 JP JP2000590990A patent/JP4405088B2/ja not_active Expired - Fee Related
- 1999-12-23 ID IDW00200101489A patent/ID29013A/id unknown
- 1999-12-23 RU RU2001120701/04A patent/RU2001120701A/ru not_active Application Discontinuation
- 1999-12-23 IL IL14379999A patent/IL143799A0/xx unknown
- 1999-12-23 US US09/868,889 patent/US6989402B1/en not_active Expired - Fee Related
- 1999-12-23 CN CNB998150576A patent/CN1186332C/zh not_active Expired - Fee Related
- 1999-12-23 KR KR1020017007766A patent/KR20010108032A/ko not_active Application Discontinuation
-
2001
- 2001-06-13 NO NO20012931A patent/NO20012931L/no not_active Application Discontinuation
- 2001-06-15 ZA ZA200104932A patent/ZA200104932B/en unknown
-
2005
- 2005-07-26 US US11/189,654 patent/US7288571B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CZ20012204A3 (cs) | 2001-11-14 |
HUP0104666A3 (en) | 2003-05-28 |
NO20012931D0 (no) | 2001-06-13 |
IL143799A0 (en) | 2002-04-21 |
HUP0104666A2 (hu) | 2002-03-28 |
TR200101834T2 (tr) | 2001-12-21 |
GB9828442D0 (en) | 1999-02-17 |
US20050282872A1 (en) | 2005-12-22 |
CN1337953A (zh) | 2002-02-27 |
WO2000039077A2 (en) | 2000-07-06 |
AU1885500A (en) | 2000-07-31 |
NZ512422A (en) | 2004-02-27 |
WO2000039077A3 (en) | 2000-09-21 |
ZA200104932B (en) | 2003-01-15 |
EP1144370A2 (en) | 2001-10-17 |
CN1186332C (zh) | 2005-01-26 |
US6989402B1 (en) | 2006-01-24 |
BR9916851A (pt) | 2001-10-16 |
NO20012931L (no) | 2001-08-21 |
AU758202B2 (en) | 2003-03-20 |
JP4405088B2 (ja) | 2010-01-27 |
JP2002533432A (ja) | 2002-10-08 |
US7288571B2 (en) | 2007-10-30 |
RU2001120701A (ru) | 2003-12-10 |
KR20010108032A (ko) | 2001-12-07 |
CA2356319A1 (en) | 2000-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ID29013A (id) | Ligan-ligan reseptor novel thiroid dan metode ii | |
ID23575A (id) | Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina | |
ID19422A (id) | Piridina dan bifenil tersubstitusi | |
ID24490A (id) | Metode untuk menggunakan dan metode pembuatan tabung oven-pijar | |
ID29591A (id) | Senyawa-senyawa kuinolina dan kuinoksalina | |
FI971620A (fi) | Autentikointimenetelmä | |
ID23684A (id) | Komposisi-polimer-organoclay dan pembuatannya | |
IS8368A (is) | Ný aðferð | |
ID19615A (id) | Tioester dan keton heterosiklik | |
DE69834401D1 (de) | Businterfacesystem und verfahren | |
ID22708A (id) | Perangkai gen dan metodanya | |
NO2010022I1 (no) | Denosumab | |
DE69819158D1 (de) | Schlüsselkopiervorrichtung und verfahren | |
ID16570A (id) | Pembuatan amina-amina dan aminonitril-aminonitril | |
DE59805235D1 (de) | Testsystem und testverfahren | |
ID26599A (id) | Turunan triazola dan imidazola | |
ID22009A (id) | Metoda dan peralatan destilasi | |
ID29053A (id) | Metode untuk menghasilkan 3-alkanoilindola dan 3-alkilindola | |
ID16889A (id) | Senyawa turunan alkilaminobenzotiazol dan benzoksazol | |
ID18456A (id) | Produksi-bersama 6-aminokapronitril dan heksametilenadiamina | |
DE69818066D1 (de) | Verbessertes detektionsverfahren | |
ID28025A (id) | Metode pembuatan aminonitril dan diamina | |
ID17973A (id) | Pembuatan amina-amina dan aminonitril-aminonitril | |
ID23258A (id) | Penarik pemberian-menyilang dan metodenya | |
FI991156A0 (fi) | Porausjärjestelmä ja -menetelmä |